Landmark CLEAR Outcomes Study Demonstrates NEXLETOL®

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin...

Related Keywords

Joanne Foody ,Sheldon Koenig ,Exchange Commission ,Twitter ,World Congress ,Esperion Corporate Communications ,Reduced Risk ,Major Adverse Cardiovascular Events ,Significantly Reduced Risk ,Myocardial Infarction ,Coronary Revascularization ,Broader Outcomes Benefits ,Secondary Prevention Compared ,Whose Outcomes Studies Were Limited ,Only Secondary Prevention ,Detailed Results Simultaneously Published ,New England Journal ,Anticipate Regulatory Filings ,Partner Milestone Payments Upon Inclusion ,Cardiovascular Risk Reduction Data ,Applicable Labels ,Conference Call ,Discuss Results ,American College ,Annual Scientific Session ,Prescribing Information ,Nasdaq Espr ,Esperion Therapeutics ,Nc ,